Efficacy of enrofloxacin against severe experimental Anaplasma marginale infections in splenectomized calves

Veterinary Therapeutics

Volumn 7, Issue 3, 2006, Pages 319-328

  Coetzee, Johann F ^a,b   Apley, Michael D ^a,b  

^a IOWA STATE UNIVERSITY   (United States)

^b KANSAS STATE UNIVERSITY   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIINFECTIVE AGENT; ENROFLOXACIN; QUINOLONE DERIVATIVE;

ANAPLASMA MARGINALE; ANAPLASMOSIS; ANIMAL; ANIMAL DISEASE; ARTICLE; CATTLE; CATTLE DISEASE; DOSE RESPONSE; DRUG EFFECT; ERYTHROCYTE; GROWTH, DEVELOPMENT AND AGING; MICROBIOLOGY; RANDOMIZATION; SPLENECTOMY; TIME; TREATMENT OUTCOME;

ANAPLASMA MARGINALE; ANAPLASMOSIS; ANIMALS; ANTI-BACTERIAL AGENTS; CATTLE; CATTLE DISEASES; DOSE-RESPONSE RELATIONSHIP, DRUG; ERYTHROCYTES; FLUOROQUINOLONES; RANDOM ALLOCATION; SPLENECTOMY; TIME FACTORS; TREATMENT OUTCOME;

ANAPLASMA MARGINALE;

EID: 33845754544     PISSN: 15283593     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (36)

1. Uilenberg G: International collaborative research: Significance of tick-borne hemoparasitic diseases to world animal health. Vet Parasitol 57:19-41, 1995.
2. Dumler JS, Barbet AF, Bekker CPJ, et al: Reorganization of genera in the families Rickettsiaceae and Anaplasmataceae in the order Rickettsiales, unification of some species of Ehrlichia with Anaplasma, Cowdria with Ehrlichia and Ehrlichia with Neorickettsia, descriptions of six new species combinations and designation of Ehrlichia equi and 'HGE agent' as subjective synonyms of Ehrlichia phagocytophila. Int J Syst Evol Microbiol 51:2145-2165, 2001.
3. Kocan KM, de la Fuente J, Guglielmone AA, Melendez RD: Antigens and alternatives for control of Anaplasma marginale infection in cattle. Clin Microbiol Rev 16(4):698-712, 2003.
4. Potgieter FT, Stoltsz WH: Anaplasmosis, in Coetzer JAW, Thompson GR, Tustin RC (eds): Infectious Diseases of Livestock with Special Reference to Southern Africa. Cape Town, Oxford University Press, 2004, pp 408-430.
5. Kuttler KL, Simpson JE: Relative efficacy of two oxytetracycline formulations and doxycycline in the treatment of acute anaplasmosis in splenectomized calves. Am J Vet Res 39(2):347-349, 1978.
6. Stewart CG, Immelman A, Grimbeek P, Grib D: The use of a short and long acting oxytetracycline for the treatment of Anaplasma marginale in splenectomized caves. J South Afr Vet Assoc 50:83-85, 1979.
7. th AVMA:160-167, 1952.
8. Roby TO: The inhibitory effect of imidocarb on experimental anaplasmosis in splenectomized calves. Res Vet Sci 13:519-522, 1972.
9. Kuttler KL: Dynamics of Anaplasma marginale in splenectomized calves treated with either imidocarb or oxytetracycline. Trop Anim Health Prod 18:91-96, 1986.
10. Kuttler KL: Pharmacotherapeutics of drugs used in treatment of anaplasmosis and babesiosis. JAVMA 176(10):1103-1108, 1980.
11. Blondeau JM: Fluoroquinolones: Mechanism of action, classification and development of resistance. Surv Opthalmol 49(suppl 2):S73-S78, 2004.
12. th World Vet Congr:60, 1991.
13. Guglielmone AA, Anziani OS, Mangold AJ, et al: Enrofloxacin to control Anaplasma marginale infections. Ann N Y Acad Sci 791:471-472, 1996.
14. Veterinary Medical Research & Development (VRMD): Anaplasma Antibody Test Kit, cELISA. Accessed June 2006 at www.vmrd.com/docs/tk/Anaplasma/ Anaplasma_2_and_5-plate_circular_060505.pdf.
15. Torioni de Echaide S, Knowles DP, McGuire TC, et al: Detection of cattle naturally infected with Anaplasma marginale in a region of endemicity by nested PCR and a competitive enzyme-linked immunosorbent assay using recombinant major surface protein 5. J Clin Microbiol 36(3):777-782, 1998.
16. Thompson JR, Kersting KW, Wass WM, et al: Splenectomy in cattle via transthoracic approach. Am J Vet Res 53(1):143-144, 1992.
17. Office International des Epizootics (OIE): Bovine anaplasmosis (Chapter 2.3.7), in Manual of Diagnostic Tests and Vaccines for Terrestrial Animals, ed 5. World Organisation for Animal Health, 2004. Accessed June 2006 at www.oie.int/eng/normes/mmanual/a_00058. htm.
18. Mutapi F, Roddam A: P values for pathogens, statistical inference from infectious-disease data. Lancet Infect Dis 2(4):219-230, 2002.
19. Zou KH, Tuncali K, Silverman SG: Correlation and simple linear regression. Radiology 227(3):617-622, 2003.
20. Ramsey FL, Schafer DW: The Statistical Sleuth, ed 2. Pacific Grove, CA, Duxbury Press, 2002.
21. Hayter AJ: A proof of the conjecture that the Tukey-Kramer multiple comparisons procedure is conservative. Ann Math Stat 12:61-75, 1984.
22. Kuttler KL: Combined treatment with a dithiosemicarbazone and oxytetracycline to eliminate Anaplasma marginale infections in splenectomized calves. Res Vet Sci 13:536-539, 1972.
23. Eriks IS, Palmer GH, McGuire TC, et al: Detection and quantitation of Anaplasma marginale in carrier cattle by using a nucleic acid probe. J Clin Microbiol 27(2):279-284, 1989.
24. French DM, Brown WC, Palmer GH: Emergence of Anaplasma marginale antigenic variants during persistent rickettsemia. Infect Immun 67(11):5834-5840, 1999.
25. Brayton KA, Meeus PFM, Barbet AF, Palmer GH: Simultaneous variation of the immunodominant outer membrane proteins, MSP2 and MSP3, during Anaplasma marginale persistence in vivo. Infect Immun 71(11):6627-6632, 2003.
26. Kieser ST, Eriks IS, Palmer GH: Cyclic rickettsemia during persistent Anaplasma marginale infection of cattle. Infect Immun 58(4):1117-1119, 1990.
27. Buening GM: Cell-mediated immune responses in calves with anaplasmosis. Am J Vet Res 34(6):757-763, 1973.
28. Drusano GL, Preston SL, Owens RC, Ambrose PG: Fluoroquinolone pharmacodynamics. Clin Infect Dis 33(12):2091-2096, 2001.
29. Kaartinen L, Pyörälä S, Moilanen M, Räisänen S: Pharmacokinetics of enrofloxacin in newborn and one-week-old calves. J Vet Pharmacol Ther 20:479-482, 1997.
30. Branger S, Rolain JM, Raoult D: Evaluation of antibiotic susceptibilities of Ehrlichia canis, Ehrlichia chaffeensis, and Anaplasma phagocytophilum by real-time PCR. Antimicrob Agents Chemother 48(12):4822-4828, 2004.
31. Klein MB, Nelson CM, Goodman JL: Antibiotic susceptibility of the newly cultivated agent of human granulocytic ehrlichiosis, promising activity of quinolones and rifamycins. Antimicrob Agents Chemother 41(1):76-79, 1997.
32. de la Fuente J, Van Den Bussche RA, Kocan KM: Molecular phylogeny and biogeography of North American isolates of Anaplasma marginale (Rickettsiaceae, Ehrlichieae). Vet Parasitol 97:65-76, 2001.
33. Palmer GH, Knowles DP, Rodriguez JL, et al: Stochastic transmission of multiple genotypically distinct Anaplasma marginale strains in a herd with high prevalence of Anaplasma infection. J Clin Microbiol 42:5381-5384, 2005.
34. Maurin M, Dakken JS, Dumler JS: Antibiotic susceptibilities of Anaplasma (Ehrlichia) phagocytophilum strains from various geographic areas in the United States. Antimicrob Agents Chemother 47(1):413-415, 2003.
35. Maurin M, Abergel C, Raoult D: DNA gyrase-mediated natural resistance to fluoroquinolones in Ehrlichia spp. Antimicrob Agents Chemother 45(7):2098-2105, 2001.
36. Brayton KA, Kappmeyer LS, Herndon DR, et al: Complete genome sequencing of Anaplasma marginale reveals that the surface is skewed to two superfamilies of outer membrane proteins. Proc Nat Acad Sci USA 102(3):844-849, 2005.